Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
A 34-year-old African American woman with sickle cell disease and history of relatively severe hemolysis, chronic leg ulcers, and mild pulmonary hypertension presented with a new ischemic stroke. Recent research has suggested a syndrome of hemolysis-associated vasculopathy in patients with sickle cell disease, which features severe hemolytic anemia and leads to scavenging of nitric oxide and its biochemical precursor l-arginine. This diminished bioavailability of nitric oxide promotes a hemolysis-vascular dysfunction syndrome, which includes pulmonary hypertension, cutaneous leg ulceration, priapism, and ischemic stroke. Additional correlates of this vasculopathy include activation of endothelial cell adhesion molecules, platelets, and the vascular protectant hemeoxygenase-1. Some known risk factors for atherosclerosis are also associated with sickle cell vasculopathy, including low levels of apolipoprotein AI and high levels of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase. Identification of dysregulated vascular biology pathways in sickle vasculopathy has provided a focus for new clinical trials for therapeutic intervention, including inhaled nitric oxide, sodium nitrite, L-arginine, phosphodiesterase-5 inhibitors, niacin, inhaled carbon monoxide, and endothelin receptor antagonists. This article reviews the pathophysiology of sickle vasculopathy and the results of preliminary clinical trials of novel small-molecule therapeutics directed at abnormal vascular biology in patients with sickle cell disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics
Lundberg, J. O., Weitzberg, E., & Gladwin, M. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2466 · Cited by 2,739
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation
Cosby, K., Partovi, K. S., Crawford, J. H., Patel, R. P., Reiter, C. D., Martyr, S., Yang, B. K., Waclawiw, M. A., Zalos, G., Xu, X., et al. (2003) · Nature Medicine · doi:10.1038/nm954 · Cited by 1,807
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationCytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver
Duranski, M. R., Greer, J. J. M., Dejam, A., Jaganmohan, S., Hogg, N., Langston, W., Patel, R. P., Yet, S.-F., Wang, X., Kevil, C. G., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22493 · Cited by 674
Kato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661 · cited 2×
“Although this enzyme is found in every tissue of the body and released during damage to that tissue, the red blood cell LDH isoenzymes appear to account for much of the variability in serum LDH levels in SCD patients at steady state.(17) Although LDH is not postulated to cause vasculopathy, it is a sensitive and easil…”
BackgroundSelf-citationShiva, S., Huang, Z., Grubina, R., Sun, J., Ringwood, L. A., MacArthur, P. H., Xu, X., Murphy, E., Darley-Usmar, V. M., & Gladwin, M. T. (2007) · Circulation Research · doi:10.1161/01.res.0000260171.52224.6b · Cited by 599
Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control
Huang, Z. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24650 · Cited by 520
Villagra, J., Shiva, S., Hunter, L. A., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2007) · Blood · doi:10.1182/blood-2006-12-061697 · Cited by 384 · cited 9×
“Further investigation is needed to determine whether these activated platelets are predisposed to form in situ pulmonary thromboses, a well-described complication of this and other forms of PH.”
BackgroundMethodInfluentialSelf-citation
Cited by
Kato, G. J., Hebbel, R. P., Steinberg, M. H., & Gladwin, M. T. (2009) · American Journal of Hematology · doi:10.1002/ajh.21475 · Cited by 349
Self-citationHeme Degradation and Vascular Injury
Belcher, J. D., Beckman, J. D., Balla, G., Balla, J., & Vercellotti, G. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2822 · Cited by 257
“Combined, these factors contribute to the overall reduced bioavailability of NO in hemolytic diseases such as sickle cell disease, which contributes to pulmonary hypertension and other comorbidities (69).”
Cardiovascular complications and risk of death in sickle-cell disease
Gladwin, M. T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00647-4 · Cited by 164
Inorganic nitrite therapy: historical perspective and future directions
Kevil, C. G., Kolluru, G. K., Pattillo, C. B., & Giordano, T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.042 · Cited by 113
Metadata
- Authors
- Kato, G. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-12-10
- Volume
- 300
- Issue
- 22
- Pages
- 2638
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1964615343
- Cited by
- 85
- References
- 17
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy. https://app.cochat.ai/papers/10.1001/jama.2008.598
- The paper
- Kato, G. J. (2008). Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy. JAMA. https://doi.org/10.1001/jama.2008.598
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.